Publication

Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries

Teisman, ACH., Buikema, H., van Veldhuisen, FJ., de Zeeuw, D. & van Gilst, WH., Apr-2000, In : Journal of Cardiovascular Pharmacology. 35, 4, p. 581-585 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Teisman, ACH., Buikema, H., van Veldhuisen, FJ., de Zeeuw, D., & van Gilst, WH. (2000). Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. Journal of Cardiovascular Pharmacology, 35(4), 581-585.

Author

Teisman, ACH ; Buikema, H ; van Veldhuisen, FJ ; de Zeeuw, D ; van Gilst, WH. / Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. In: Journal of Cardiovascular Pharmacology. 2000 ; Vol. 35, No. 4. pp. 581-585.

Harvard

Teisman, ACH, Buikema, H, van Veldhuisen, FJ, de Zeeuw, D & van Gilst, WH 2000, 'Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries', Journal of Cardiovascular Pharmacology, vol. 35, no. 4, pp. 581-585.

Standard

Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. / Teisman, ACH; Buikema, H; van Veldhuisen, FJ; de Zeeuw, D; van Gilst, WH.

In: Journal of Cardiovascular Pharmacology, Vol. 35, No. 4, 04.2000, p. 581-585.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Teisman ACH, Buikema H, van Veldhuisen FJ, de Zeeuw D, van Gilst WH. Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. Journal of Cardiovascular Pharmacology. 2000 Apr;35(4):581-585.


BibTeX

@article{1f77b6576e224922a2445f6f18ca0824,
title = "Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries",
abstract = "Dopaminergic agonists remain of interest in the treatment of heart failure; however, concomitant stimulation of alpha- and beta-receptors should be avoided. This study evaluates the dopaminergic and adrenergic (vasodilating) properties of Z1046, epinine (the active metabolite of ibopamine), and dopamine. Isotonic contraction experiments were performed on human internal mammary artery rings in vitro. alpha(1)-Antagonistic effects of Z1046 were demonstrated by performing cumulative dose-response curves with the selective alpha(1)-agonist phenylephrine in the presence of Z1046. Furthermore, both alpha(1)- and dopamine-mediated receptor effects of Z1046, epinine, and dopamine were studied by performing cumulative dose-response relations both at baseline and in precontracted artery rings both with and without the D-1-like antagonist SCH23390. In contrast to both epinine and dopamine, Z1046 is devoid of alpha(1)-receptor-mediated contraction. Furthermore, Z1046, epinine, and dopamine induced direct dopamine receptor-mediated vasodilation when interfering alpha(1) effects were blocked. In contrast to epinine and dopamine, Z1046 is devoid of vasoconstricting properties at higher dosages. Because of its D-1-like agonistic and alpha(1)- antagonistic properties, Z1046 is an effective vasodilator in the whole dosage range. Because of its total receptor profile, Z1046 appears to be more favorable for treatment of heart failure than is ibopamine.",
keywords = "epinine, dopamine, Z1046, human arteries, DA1 RECEPTOR AGONIST, HEART-FAILURE, IBOPAMINE, VASCULATURE, FENOLDOPAM",
author = "ACH Teisman and H Buikema and {van Veldhuisen}, FJ and {de Zeeuw}, D and {van Gilst}, WH",
year = "2000",
month = "4",
language = "English",
volume = "35",
pages = "581--585",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
number = "4",

}

RIS

TY - JOUR

T1 - Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries

AU - Teisman, ACH

AU - Buikema, H

AU - van Veldhuisen, FJ

AU - de Zeeuw, D

AU - van Gilst, WH

PY - 2000/4

Y1 - 2000/4

N2 - Dopaminergic agonists remain of interest in the treatment of heart failure; however, concomitant stimulation of alpha- and beta-receptors should be avoided. This study evaluates the dopaminergic and adrenergic (vasodilating) properties of Z1046, epinine (the active metabolite of ibopamine), and dopamine. Isotonic contraction experiments were performed on human internal mammary artery rings in vitro. alpha(1)-Antagonistic effects of Z1046 were demonstrated by performing cumulative dose-response curves with the selective alpha(1)-agonist phenylephrine in the presence of Z1046. Furthermore, both alpha(1)- and dopamine-mediated receptor effects of Z1046, epinine, and dopamine were studied by performing cumulative dose-response relations both at baseline and in precontracted artery rings both with and without the D-1-like antagonist SCH23390. In contrast to both epinine and dopamine, Z1046 is devoid of alpha(1)-receptor-mediated contraction. Furthermore, Z1046, epinine, and dopamine induced direct dopamine receptor-mediated vasodilation when interfering alpha(1) effects were blocked. In contrast to epinine and dopamine, Z1046 is devoid of vasoconstricting properties at higher dosages. Because of its D-1-like agonistic and alpha(1)- antagonistic properties, Z1046 is an effective vasodilator in the whole dosage range. Because of its total receptor profile, Z1046 appears to be more favorable for treatment of heart failure than is ibopamine.

AB - Dopaminergic agonists remain of interest in the treatment of heart failure; however, concomitant stimulation of alpha- and beta-receptors should be avoided. This study evaluates the dopaminergic and adrenergic (vasodilating) properties of Z1046, epinine (the active metabolite of ibopamine), and dopamine. Isotonic contraction experiments were performed on human internal mammary artery rings in vitro. alpha(1)-Antagonistic effects of Z1046 were demonstrated by performing cumulative dose-response curves with the selective alpha(1)-agonist phenylephrine in the presence of Z1046. Furthermore, both alpha(1)- and dopamine-mediated receptor effects of Z1046, epinine, and dopamine were studied by performing cumulative dose-response relations both at baseline and in precontracted artery rings both with and without the D-1-like antagonist SCH23390. In contrast to both epinine and dopamine, Z1046 is devoid of alpha(1)-receptor-mediated contraction. Furthermore, Z1046, epinine, and dopamine induced direct dopamine receptor-mediated vasodilation when interfering alpha(1) effects were blocked. In contrast to epinine and dopamine, Z1046 is devoid of vasoconstricting properties at higher dosages. Because of its D-1-like agonistic and alpha(1)- antagonistic properties, Z1046 is an effective vasodilator in the whole dosage range. Because of its total receptor profile, Z1046 appears to be more favorable for treatment of heart failure than is ibopamine.

KW - epinine

KW - dopamine

KW - Z1046

KW - human arteries

KW - DA1 RECEPTOR AGONIST

KW - HEART-FAILURE

KW - IBOPAMINE

KW - VASCULATURE

KW - FENOLDOPAM

M3 - Article

VL - 35

SP - 581

EP - 585

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -

ID: 3855202